Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Aug 11, 2017

Keywords

ClinConnect Summary

Given the growing number of patient contacts at our day-care center, there is a continuous search to further improve the flow and to shorten the time spent per patient at the day-care center, without loss of quality in care.

In order to achieve this goal, this study wants to compare the administration of Multigam IV 5% and Multigam IV 10%. Multigam 5% and Multigam 10% are immunoglobulin solutions that are administered to strengthen the body's natural defense system (immune system). In case of recurrent infections, patients with an immunodeficiency secondary to a hematologic disorder can be...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age =\> 18 years
• • Immunodeficiency secondary to a hematologic disorder
• • Patient has received at least 2 Multigam IV 5% administrations
• • Patient may not have had any adverse events (grade 2 or higher according to CTCAE v4.03) during the last 2 Multigam IV 5% administrations
• • Patient needs at least 2 more immunoglobulin administrations
• • Signed informed consent
• Exclusion Criteria:
• • Patient has received less than 2 Multigam IV 5% administrations
• • Patient has had an adverse event (grade 2 or higher according to CTCAE v4.03) during the last 2 Multigam IV 5% administrations
• • Refusal to sign informed consent